Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles
AbstractCombining DNA damage repair inhibitors and chemotherapeutic agents is an emerging strategy in cancer treatment. In this study, we engineered the polycation nanoparticle (NP), which co-encapsulated DNA damage repair inhibitor Dbait and chemotherapeutic drug Docetaxel (Dtxl), using H1 nanopoly...
Main Authors: | Nianli Liu, Jiayin Ji, Hui Qiu, Zhiying Shao, Xin Wen, Aoxing Chen, Senbang Yao, Xingying Zhang, Hong Yao, Longzhen Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Artificial Cells, Nanomedicine, and Biotechnology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21691401.2019.1703726 |
Similar Items
-
Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
by: Jun-Hong Li, et al.
Published: (2023-01-01) -
Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
by: Victor Omoboyede, et al.
Published: (2023-04-01) -
A tumor microenvironment-responsive micelle co-delivered radiosensitizer Dbait and doxorubicin for the collaborative chemo-radiotherapy of glioblastoma
by: Shuyue Zhang, et al.
Published: (2022-08-01) -
Integrated radiochemotherapy study of ZIF-8 coated with osteosarcoma-platelet hybrid membranes for the delivery of Dbait and Adriamycin
by: Longhai Du, et al.
Published: (2023-02-01) -
Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)